1289038-89-6

Basic information

• Product Name: 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde
• Synonyms: 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde;3-Hydroxy-5-Methoxyisonicotinaldehyde
• CAS NO: 1289038-89-6
• Molecular Formula: C7H7NO3
• Molecular Weight: 153.13538
• EINECS: -0
• Mol File: 1289038-89-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde(1289038-89-6)
• EPA Substance Registry System: 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde(1289038-89-6)

Safety Data

• Hazardous Substances Data: 1289038-89-6(Hazardous Substances Data)

Usage

General Description

3-Hydroxy-5-Methoxypyridine-4-carbaldehyde is a chemical compound with the molecular formula C8H7NO3. It is a derivative of pyridine and contains a hydroxyl group and a methoxy group. 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the field of medicinal chemistry and drug discovery due to its biological activities and pharmacological properties. Additionally, 3-Hydroxy-5-Methoxypyridine-4-carbaldehyde has been studied for its potential antioxidant and anti-inflammatory properties, making it a promising candidate for further research and development in the pharmaceutical industry.

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 109345-94-0 3-hydroxy-5-methoxypyridine 
• 445264-60-8 3-methoxy-5-pyridineboronic acid pinacol ester 
• 204862-70-4 3,5-dimethoxyisonicotinaldehyde 
• 18677-48-0 3,5-dimethoxypyridine 
• 71902-33-5 3,5-difluoropyridine 

Relevant articles and documents

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ～150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).

INHIBITORS OF THE KYNURENINE PATHWAY

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.